PSA Today Valentine's Day: End-of-week profits taken / Look at the earnings! / Kioxia, Nissan, SMC, Daifuku, BASE Inc, Rakuten, Appier, Intermestic, Sanrio, GNI Group, Nxera – Nikkei 225 -0.79% | ¥$152.55

PSA Today Japan Market Comment by Pelham Smithers, Julie Boote, Joel Scheiman, William Nestuk, Thao Nguyen, Lindsay Whipp, Hiroyuki Terada and Nia Dokova
Tags: Sony (6758 JT), Ricoh (7752 JT), Nissan Motor (7201 JT), Nexon (3659 JT), PKSHA (3993 JT), PeptiDream (4587 JT), Modec (6269 JT), Trend Micro (4704 JT), Gumi (3903 JT), Metaplanet (3350 JT), Ceres (3696 JT), Monex (8698 JT), Diamond Electric (6699 JT), Nikkiso (6376 JT), DeepSeek (pvt), Hitachi (6501 JT), NEC (6701 JT), Fujikura (5803 JT), Renesas (6723 JT), Appier (4180 JT), SRE Holdings (2980 JT), Intel (INTC US), Samsung Electronics (005930 KS), Tokyo Electron (8035 JT), Electronic Arts (EA US), Ubisoft (UBI FP), Konami (9766 JT), Capcom (9697 JT), Square Enix (9684 JT), Koei Tecmo (3635 JT), Bandai Namco (7832 JT), Mixi (2121 JT), Akatsuki (3932 JT), DeNA (2432 JT), MHI (7011 JT), KHI (7012 JT), Kajima (1812 JT), Shimizu (1803 JT), Vanke (2202 HK), Chugai Pharm (4519 JT), Sysmex (6869 JT), Kioxia (285A JT), SMC (6273 JT), Daifuku (6383 JT), BASE Inc (4477 JT), Estore Corporation (4304 JT), Rakuten (4755 JT), Intermestic (262A JT), Sanrio (8136 JT), GNI Group (2160 JT), Pulmatrix (PULM US), Nxera Pharma (4565 JT), Novartis (NOVN SW), AbbVie (ABBV US), Neurocrine (NBIX US), Bristol Myers Squibb (BMY US), Cerevel Therapeutics
Main Points
 Japan shares slide as earnings fail to offset end of week profit-taking
 What now for Japanese stocks as results season winds down?
 Kioxia reports FY24 Q3 OP of ¥123bil vs a loss a year ago; guiding for a YoY decline in FYQ4 OP
 Details of Nissan’s FY24 Q3 earnings
 SMC FY24 Q3 OP -14% YoY disappoints
 Daifuku produces record FY24 OP and FY25 OP guidance
 BASE Inc’s FY24 Results and FY25 Guidance Miss
 Rakuten Achieves First OP in Five Years
 Appier’s FY24 results close to consensus estimates, but company expects to miss FY25 OPM goal
 Intermestic FY24 ahead of guidance; FY25 outlook seems conservative
 Hello Kitty 50th anniversary boosts Sanrio’s FY24 Q3 OP
 GNI Group Q4 loss as Cullgen merger delayed to 2025
 Nxera Pharma misses full-year FY24 estimates